Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 2.

Cloughesy, Timothy; Finocchiaro, Gaetano; Belda-Iniesta, Cristóbal; Recht, Lawrence; Brandes, Alba A; Pineda, Estela; Mikkelsen, Tom; Chinot, Olivier L; Balana, Carmen; Macdonald, David R; Westphal, Manfred; Hopkins, Kirsten; Weller, Michael; Bais, Carlos; Sandmann, Thomas; Bruey, Jean-Marie; Koeppen, Hartmut; Liu, Bo; Verret, Wendy; Phan, See-Chun; Shames, David S (2017). Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O(6)-Methylguanine-DNA Methyltransferase Biomarker Analyses. Journal of Clinical Oncology, 35(3):343-351.

Wick, Wolfgang; Gorlia, Thierry; Bady, Pierre; Platten, Michael; van den Bent, Martin J; Taphoorn, Martin J B; Steuve, Jonathan; Brandes, Alba A; Hamou, Marie-France; Wick, Antje; Kosch, Markus; Weller, Michael; Stupp, Roger; Roth, Patrick; Golfinopoulos, Vassilis; Frenel, Jean-Sebastien; Campone, Mario; Ricard, Damien; Marosi, Christine; Villà, Salvador; Weyerbrock, Astrid; Hopkins, Kirsten; Homicsko, Krisztian; Lhermitte, Benoit; Pesce, Gianfranco Angelo; Hegi, Monika E (2016). Phase II study of radiotherapy and temsirolimus versus radiochemotherapy with temozolomide in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation (EORTC 26082). Clinical Cancer Research, 22(19):4797-4806.

This list was generated on Fri Sep 20 03:06:40 2019 CEST.